Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/10—Spiro-condensed systems

Definitions

• R is hydrogen, methyl, ethyl
• R is hydrogen or methyl
• R and R are hydrogen, methyl or wherein R is hydrogen, chloro or fluoro; wherein R is hydrogen, or fluoro with the proviso that R is not chloro; and wherein R is hydrogen, chloro, fluoro, bromo, nitro, or trifluoromethyl is produced by converting a compound of formula I:
• R R R R are defined as above to the 4- lithio (or potassium) compound II. then treating Il with a dihaloethane to afford the 4-(2-haloethyl) comwherein X is bromo or chloro, and R R R and R. are defined as above, and cyclizing [II with butyl lithium, lithium diisopropyl amide, potassium hydride, or potassium butoxide, or other alkali metal base to obtain compound IV above.
• the compounds of formula IV above as well as the pharmacologically acceptable acid addition salts thereof have sedative tranquilizing, antianxiety and muscle-relaxant activity and are useful in the treatment of mammals, including man, and birds,
• R5 is hydrogen or methyl
• R and R are hydrogen, methyl or wherein R is hydrogen, chloro, or fluoro
• R is hydrogen, or fluoro if R is fluoro
• R is hydrogen, chloro, fluoro, bromo, nitro, or trifluoromethyl
• X is chloro or bromo
• A is lithium, sodium, or potassium.
• the invention includes also the pharmacologically acceptable acid addition salts of compounds of formula IV.
• the process of this invention comprises: treating a compound of formula I with butyl lithium, potassium hydride, lithium diisopropylamide or a potassium alkoxide e.g., butoxide, to obtain compound II; treating II with afi-dihaloethane in which the halogen is chloro or bromo to obtain compound Ill; and treating III with butyllithium, lithium diisopropylamide, potassium butoxide, potassium hydride, or other alkali metal base to obtain compound IV.
• the new final compounds of formula IV and their pharmacologically acceptable acid addition salts thereof are essentially products which are useful in mammals to counteract anxiety and to produce tranquilization without strong hypnotic effects.
• R' is hydrogen. methyl. or (dimethylamino)- methyl; wherein R is hydrogen. chloro. or fluoro. wherein R is hydrogen. or fluoro providing R is not chloro. and wherein R' is hydrogen, chloro. fluoro, or trifluoromcthyl; and the pharmacologically acceptable acid addition salts thereof.
• R is hydrogen. methyl. or (dimethylamino)- methyl; and wherein R' and R" are hydrogen or chloro. and the pharmacologically acceptable acid addition salts thereof.
• the new compounds of formula IV including the more desirable compounds of formulae IVA and IVB and the pharmacologically acceptable acid addition salts thereof are essentially sedating tranquilizing agents which also have muscle-relaxing activity.
• mice 50% of the mice failed doing Dish test: Mice in Petri dishes 10 cm. diameter, 5 cm. high. partially embedded in wood shavings), climb out in a very short time. when not treated. Mice remaining in the dish for more than 3 minutes indicates tranquilization. ED equals the dose of test compound at which 50% of the mice remain in the dish.
• Pedestal test The untreated mouse leaves the pedestal in less than a minute to climb back to the floor of the standard mouse box. Tranquilized mice will stay on the pedestal for more than I minute.
• Nicotine antagonism test Mice in a group of 6 are injected with the test compounds. Thirty minutes later the mice including control (untreated) mice are injected with nicotine salicylate (2 mg./kg.). The control mice show overstimulation. i.e.. (I) running convulsions followed by (2) tonic extensor fits; followed by (3) death. The data obtained for 8'-chloro-6'-(o-chlorophenyl)- I methylspiro[cyclopropane- I .4'-[4H I-striazolo[4.3-a]-[ l .4]benzodiazepine] (A):
• the pharmaceutical forms contemplated by this invention include pharmaceutical compositions suited for oral. parenteral. and rectal use. cg. tablets. powder packets. cachets. dragees. capsules. solutions. suspensions. sterile injectable forms. suppositories. bougics. and the like. Suitable diluents or carriers such as carbohydrates (lactose). proteins. lipids. calcium phosphate. cornstarch. stearic acid. mcthylcellulose and the like may be used as carriers or for coating purposes. Water or oils. e.g.. coconut oil. sesame oil. safflower oil. cottonseed oil. peanut oil. may be used for preparing solutions or suspensions of the active drug. sweetening. coloring. and flavoring agents may he added.
• the compounds of formula IV can be used in unit dosages of (1.2 to 25 mg./kg.. preferably between 0.5 and mg./kg.. in oral or injectable preparations as described above. to alleviate tension and anxiety in mammals. or birds. such as. e.g.. occurs when animals are in travel. For larger mammals lower dosages are indicated. For the treatment of anxiety in mammals. unit dosage forms of 0.1 to 3 mg/kg. are indicated. In large mammals kg. to l()() kg.. l to 20 mg. unit dosage is considered satisfactory.
• the starting material I of this application are known compounds of the structure:
• R is hydrogen or methyl.
• R and R are hydrogen. methyl. or
• A/CH2 '3 in carrying out the process of this invention a selected compound of formula I is reacted with an alkali metal organic compound capable of exchanging a 4- hydrogen of compound I with the alkali metal. e.g.. lithium or potassium.
• an alkali metal organic compound capable of exchanging a 4- hydrogen of compound I with the alkali metal.
• e.g.. lithium or potassium e.g. lithium or potassium.
• This is achieved by the reaction of compound I with. e.g... butyl lithium. potassium tertiary butoxide. potassium or sodium hydride. or lithium diisopropylamide which is generally prepared from methyllithium and diisopropylamine and the like.
• This reaction is generally carried out at temperatures of -6() to +l() C. in an inert organic solvent. e.g., ether. tetrahydrofuran, 1.2-dimethoxyethane or the like. preferably in a nitrogen atmosphere and with avoidance of any
• the thus-obtained product II is immediately reacted with a selected afi-dihaloethane. in which halogen is chloro or bromo, to give the product Ill.
• the product III is isolated and recovered by conventional methods e.g.. extraction. chromatography and crystallization.
• Compound III is cyclized with a base, e.g.. butyl lithium or lithium diisopropylamide or potassium hydride in an inert organic solvent.
• Solvents useful in this reaction are tetrahydrofuran. dioxane. 1.2 dimethoxyethane. ether. dipropylether or the like.
• the addition of the reactant. butyl lithium. to the solution of compound III is usually carried out at temperatures between 4() to [0 C. After the reactant has been added the stirred solution is allowed to warm to room temperatures. 2()3() C.. and then poured into an icewater mixture.
• the aqueous solution is made basic with an alkali hydroxide. e.g..
• the chloroform extract is dried over anhydrous sodium sulfate, concentrated in vacuo to an oil, chromatographed over silica gel by eluting with methanol/chloroform mixtures and crystallized.
• the thus-obtained 8-chloro-4-( 2- chloroethyl)-1-methyl-6-(o-chlorophenyl)-4H-striazolo[4,3-a][1,4]benzodiazepine has a melting point of 197 to 198 C.
• EXAMPLE 3 8-Chloro-4-(Z-chloroethyl)-1-methyl-6-(ochlorophenyl )-4H-s-triazolo[4, 3- a][ 1,4]benzodiazepine (4.05 g., 10.0 mmol), dissolved in ml. of dry tetrahydrofuran, is added slowly to a cold (40 to 10 C.) solution of 12.0 mmol of butyl lithium in tetrahydrofuran. The solution is stirred for 1 hour, while warming to room temperature, and then poured onto ice, made basic with a aqueous sodium hydroxide solution and extracted with chloroform.
• Example 4 l-Methyl-4-( 2-chloroethyl )-6-phenyl-8-chloro-4H-striazolo[4,3-a][ 1 ,4lbenzodiazepine 49.6 Mmol of methyllithium in 40 ml. of cold 1,2- dimethoxyethane at 60 C. is treated with 6.08 g. (60.0 mmol) of diisopropylamine and stirred A hour. To this is added a slurry of 12.35 g. (40.0 mmol) of 8- chloro- 1 -methyl-6-phenyl-4H-s-triazolo[4,3- a][1.4]benzodiazepine in a mixture of 40 ml.
• Example 5 8 -Chloro-1 -methyl-6-phenylspiro[cyclopropane- 1,4'-[4H ]-s-triazolo[4,3-a][ 1,4]benzodiazepine]
• 8-chloro-1- methyl-4-( 2-chloroethyl )-6-phenyl-4H-s-triazolo[ 4,3- a][l,4]-benzodiazepine in tetrahydrofuran is reacted with butyl lithium to give 8-chloro-1-methyl-6'- phenylspiro[cyclopropane-l ,4-[4H]-s-triazolo[ 4,3- a] 1 ,4lbenzodiazepine].
• EXAMPLE 6 8-Chloro-4-lithio-6-( o-chlorophenyl )-4H-striazolo[4,3-a][ 1 ,4]benzodiazepine 1n the manner given in Example 1, 8-chloro-6-(ochlorophenyl)-4H-s-triazolo[4,3- a][l,4]benzodiazepine in tetrahydrofuran is reacted with lithium diisopropylamide, prepared in situ, to give 8-chloro-4-lithio-6-( o-chlorophenyl )-4H-striazolo[4,3-a ⁇ [ 1,4]benzodiazepine in solution.
• EXAMPLE 7 EXAMPLE 8 8 '-Chloro-6 o-chlorophenyl )spiro[cyclopropane- In the manner given in Example 3, 8-chloro-4-(2- chloroethyl )-6-( o-chlorophenyl )-4H-s-triazolo 4,3- a][l,4]-benzodiazepine in tetrahydrofuran is reacted with butyl lithium to give 8'-chloro-6'-(ochlorophenyl )spiro[cyclopropanel ,4-[4H ]-striazolo[4,3-a][ 1,4]benzodiazepine].
• chlorophenyl spiro-[eyclopropanel ,4'-[4H 1-striazolo[4 3-a][ l,4]benzodiazepine]; l'-ethyl-6'- phenylspiro[cyclopropanel ,4 1 [4H s-triazolo- [4,3-al[ 1,4]benzodiazepine]; 6'-(o-chlorophenyl )spiro[ cyclopropanel ,4'-[4H ]-striazolo-[ 4,3-a][ 1,4]benzodiazepine];
• the pharmacologically acceptable acid addition salts of compounds of formula IV can be prepared and isolated by conventional processes, such as reacting a compound of formula IV with a selected pharmaeologically acceptable acid.
• Such acids include hydrochloric, hydrobromic, phosphoric, sulfuric, acetic, tartaric, lactic, citric, malic, maleic, fumaric. methanesulfonic, benzenesulfonic, cyclohexanesulfamic acids, toluenesulfonic, and the like.
• the reaction is conveniently performed in an organic solvent, e.g., ether, dioxane or tetrahydrofuran, ethanol, methanol, ethyl acetate; the salts can be recovered by crystallization, precipitation or by evaporating the solvent.
• organic solvent e.g., ether, dioxane or tetrahydrofuran, ethanol, methanol, ethyl acetate
• R is hydrogen, methyl, ethyl
• R is hydrogen or methyl
• R and R are hydrogen, methyl or IVA wherein R is hydrogen, methyl, or (dimethylamino)- methyl; wherein R is hydrogen, chloro or fluoro; wherein R is hydrogen, or fluoro providing R is not chloro; and wherein R, is hydrogen, chloro, fluoro, or trifluoromethyl, and the pharmacologieally acceptable acid addition salts thereof.
• R' is methyl, R and R" are chloro and the compound is therefore 8'-chloro-l '-methyl-6-(ochlorophenyl )spiro[cyclopropane l ,4'-[4H ]-striazolo[ 4,3-a][ l ,4]benzodiazepine].
• R is hydrogen
• R' and R" are chloro and the compound is therefore 8'-chloro-6'-(ochlorophenyl )spiro[cyclopropanel ,4'-[4H ]-striazolo[4,3-a][ l ,41benzodiazepine].
• R is methyl, R"., is hydrogen, R'-; is chloro and the compound is therefore I '-methyl-6'-(ochlorophenyl )spiro[cyclopropane-l ,4'-[4H]-striazolo[4,3-a][ 1,4]benzodiazepine].
• R is methyl, R and and R are hydrogen, R is fluoro and the compound is therefore 8-fluoro-l '-methyl-6'- phenylspiro[cyciopropanel l ,4-[4H]-s-triazolo[4,3- a][ l,4]-benzodiazepine].
• R is (dimethylamino)methyl
• R' is hydrogen
• R is chloro and the compound is therefore 8-chlorol [(dimethylaminomethyl 1-6- phenylspiro[cyclopropane-l ,4-[4H ]-s-triazolo[4,3- a][ 1,4]benzodiazepine].
• R is (dimethylamino)methyl
• R' and R are chloro
• the compound is therefore 8'-chloro-l [(dimethylamino)-metheyl]-6'-(ochlorophenyl )spirolcyclopropanel ,4 '-[4H]-striazolo[ 4,3-a][ l ,4]benzodiazepine].
• R is hydrogen or methyl
• R and R are hydrogen, methyl or CH Uta-C 2 wherein R is hydrogen, chloro, or fluoro; wherein R is hydrogen, or fluoro if R is fluoro; and wherein R is hydrogen, chloro, fluoro, bromo, nitro, trifluoromethyl which comprises: (l) treating a compound of formula l:
• R R R and R are defined as above with a reagent to produce a 4-alkali metal compound ll:
• R R R and R are defined as above and A is an alkali metal atom, (2) treating ll with an a,B-dihaloethane X'CH -CH X, wherein X and X' are chloro or bromo, to obtain a compound of formula Ill:

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Fodder In General (AREA)

Priority Applications (5)

Applications Claiming Priority (1)

Publications (1)

Family

ID=24092932

Family Applications (1)

Country Status (5)

Cited By (4)

Families Citing this family (1)

Citations (1)

• 1974
  • 1974-11-20 US US525363A patent/US3910944A/en not_active Expired - Lifetime
• 1975
  • 1975-10-13 GB GB4176775A patent/GB1456358A/en not_active Expired
  • 1975-10-15 JP JP50124220A patent/JPS5165799A/ja active Pending
  • 1975-10-31 DE DE19752548737 patent/DE2548737A1/de active Pending
  • 1975-11-20 FR FR7535547A patent/FR2291758A1/fr active Granted

Patent Citations (1)

Also Published As

Similar Documents